SMS Lifesciences India Ltd. shows a mixed performance against its peers, with notable strengths in profitability metrics but weaknesses in growth. The company is undervalued based on its PEG ratio, and while it faces challenges in revenue growth, it maintains a manageable debt level. Key peers like Cipla and Dr. Reddy's Laboratories stand out for their robust profitability and efficient operations, while companies like Sun Pharma and Divi's Laboratories appear overvalued given their high PE ratios.

• • SMS Lifesciences shows poor revenue growth but has reasonable margins.
• • Cipla and Dr. Reddy's lead in profitability metrics like ROE and PAT margin.
• • Sun Pharma and Divi's are overvalued based on high PE ratios compared to their growth rates.
• • Financially weak companies include those with high debt-to-equity ratios and low profitability.